- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05397613
STAIR for Trauma and Emotion Dysregulation
25. maj 2022 opdateret af: Sanno Zack, Stanford University
Examining the Effectiveness of STAIR as an Alternative to DBT for Patients With Emotion Dysregulation and PTSD
This study will examine the impact of Skills Training in Affective and Interpersonal Regulation (STAIR) group, using self-report measures, on Posttraumatic Stress Disorder (PTSD), emotional dysregulation, borderline personality disorder symptoms, global psychopathology, and access to quality mental health care.
Aims include assessing the feasibility of STAIR, reducing patients' trauma and emotion dysregulation symptoms, examining whether STAIR may be used as an alternative to DBT for patients on the DBT, and improving patient satisfaction and clinic efficiency
Studieoversigt
Status
Tilmelding efter invitation
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
30
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
California
-
Stanford, California, Forenede Stater, 94305
- Stanford University
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Be 18 years or older.
- Have a DSM-5 diagnosis and/or symptoms for which DBT is an indicated treatment
- Meet DSM-5 criteria for a diagnosis of posttraumatic stress disorder (PTSD)
- Meet criteria at a subclinical level for BPD (a minimum of three symptoms)
- Must be able to make group commitments for attendance, safety, and sobriety during group
Exclusion Criteria:
- If currently receiving individual therapy that follows the DBT protocol or is an evidence-based trauma-focused therapy
- If the STAIR therapy group is determined to be clinically contraindicated
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: STAIR
Participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
Eksperimentel: Waitlist control
First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures.
Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of participants who complete the STAIR intervention
Tidsramme: Week 12
|
This number will include those who attend the 12 weeks of STAIR with no more than three missed sessions
|
Week 12
|
Total score of patient treatment satisfaction ratings
Tidsramme: Week 12
|
Calculate the total score for each participant on the Client Satisfaction Questionnaire-8, and find the average of those scores.
Scores are summed across items.
Items 2, 4, 5, and 8 are reverse scored.
Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
|
Week 12
|
Frequency of participant attendance
Tidsramme: Week 1 through Week 12
|
Calculate the number of patients who attended each week of the STAIR treatment.
|
Week 1 through Week 12
|
Change in emotion regulation total score from baseline to Week 12
Tidsramme: Baseline to Week 12
|
Problems with emotion regulation will be assessed using the Difficulty in Emotion Regulation Scale.
Total score ranges from 36 to 180.
Higher scores indicate greater problems with emotion regulation.
|
Baseline to Week 12
|
Change in the severity of posttraumatic stress disorder symptom total score from baseline to Week 12
Tidsramme: Baseline to Week 12
|
The severity of posttraumatic stress disorder symptoms is measured using the PCL-5.
Items are rated using a 5-point likert scale ranging from 0 "not at all" to 4 "extremely."
All 20 items are summed to obtain a total score (0 to 80), higher scores indicate higher severity of PTSD symptoms.
|
Baseline to Week 12
|
Change in Borderline symptom severity total score from baseline to Week 12
Tidsramme: Baseline and Week 12
|
Using the Borderline Evaluation of Severity Scale comprising of 15 items using a likert scale rated from 5 "Almost Always" to 1 "Almost Never."
There are three subscales that comprise this measure: (1) Thoughts and Emotions (2) Behaviors-Negative and (3) Behaviors-Positive.
The total for each subscale is determined to score the BEST.
The scores of subscales A and B are then added together and the total from subscale C is subtracted.
A correction factor of 15 is added to yield the final score which can range from 12 (best) to 72 (worst).
|
Baseline and Week 12
|
Change in Borderline Symptom List-23 total score from baseline to Week 12
Tidsramme: Baseline and Week 12
|
This measure assesses feelings and experiences commonly endorsed by patients with BPD.
The 23-item scale utilizes a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very strong."
The BSL-23 is scored by summing up the scores for all of the items.
Total score ranges from 0 to 92, with higher scores reflecting more severe borderline personality symptoms.
|
Baseline and Week 12
|
Change in current symptoms of psychopathology and psychological distress total score from baseline to Week 12
Tidsramme: Baseline and Week 12
|
The Symptom Checklist-90-Revised is a 90-item multidimensional self-report symptom measure that assesses current symptoms of psychopathology and psychological distress.
The items were scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely).
It assesses nine symptom dimensions (somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism).
Global measures are provided to summarize overall distress, and these include the Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total.
Raw scores are calculated by dividing the sum of scores for a specific dimension by the number of items in the dimension.
Global severity index is calculated by summing the scores of the nine dimensions and additional items, then dividing by the total number of responses.
Total score ranges from 0 to 360.
Higher scores indicate worsening of disease.
|
Baseline and Week 12
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Sanno Zack, PhD, Stanford Universtiy
- Ledende efterforsker: Emily Livermore, PsyD, Stanford University
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Forventet)
15. juni 2022
Primær færdiggørelse (Forventet)
15. juni 2025
Studieafslutning (Forventet)
15. juni 2025
Datoer for studieregistrering
Først indsendt
24. maj 2022
Først indsendt, der opfyldte QC-kriterier
25. maj 2022
Først opslået (Faktiske)
31. maj 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
31. maj 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
25. maj 2022
Sidst verificeret
1. maj 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 64219
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med STAIR
-
University of California, San FranciscoPatient-Centered Outcomes Research Institute; Stanford UniversityIkke rekrutterer endnu
-
Boston Medical CenterNational Institute of Mental Health (NIMH)AfsluttetPost traumatisk stress syndromForenede Stater
-
University of AmsterdamAfsluttetPosttraumatisk stresslidelse (PTSD)Holland
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)Ikke rekrutterer endnuPost traumatisk stress syndrom | Misbrug af flere stofferForenede Stater